{"ATC Code":"N05CD03","Abbreviation":"","Aliases":["Rohypnol","Narcozep","Roipnol","Fluninoc","Primun","flunipam","Flunitrazepamum","Fluridrazepam","Silece","Ro 5-4200"],"Biological Half-Life":"18-26 hours","CAS":"1622-62-4","ChEBI":"CHEBI:31622","ChEMBL":"CHEMBL13280","ChemicalClasses":["benzodiazepine"],"Chirality":"achiral","Color/Form":"Pale yellow needles from methylene chloride-hexane","DEA no":2763,"Decomposition":"When heated to decomposition it emits toxic fumes of /fluoride \u0026 nitrogen oxides/.","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":1,"Upper":1},"Heavy":{"Lower":2,"Upper":5.699999999999998},"Light":{"Lower":1,"Upper":1},"Strong":{"Lower":1,"Upper":2},"Threshold":{"Lower":0.5,"Upper":1}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","Drug Indication":"For short-term treatment of severe insomnias, that are not responsive to other hypnotics.","Drug Warnings":"Flunitrazepam is tasteless and odorless and has been misused to incapacitate the victim and produce amnesia in sexual assaults and drug-facilitated rape ('date rape'). A 1-mg dose may produce impairment for 8-12 hrs. Some manufacturers have incorporated a blue dye into flunitrazepam tablets to increase visibility when placed into drinks but caution is still necessary as it has been reported that blue tropical drinks and punches are being used to overcome this.","DrugClasses":[],"EINECS":"216-597-8","European Community (EC) Number":"216-597-8","Human Drugs":"Breast Feeding; Lactation; Milk, Human; Hypnotics and Sedatives; Anti-Anxiety Agents; Benzodiazepines","IUPACName":"5-(2-fluorophenyl)-1-methyl-7-nitro-3H-1,4-benzodiazepin-2-one","Impurities":["2′-fluoro-2-methylamino-5-nitrobenzophenone","3-amino-4-(2-fluorophenyl)-1-methyl-6-nitroquinolin-2(1h)-one","7-aminodemethylflunitrazepam","norflunitrazepam"],"InChI":"InChI=1S/C16H12FN3O3/c1-19-14-7-6-10(20(22)23)8-12(14)16(18-9-15(19)21)11-4-2-3-5-13(11)17/h2-8H,9H2,1H3","InChIKey":"PPTYJKAXVCCBDU-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Agents that alleviate ANXIETY, tension, and ANXIETY DISORDERS, promote sedation, and have a calming effect without affecting clarity of consciousness or neurologic conditions. ADRENERGIC BETA-ANTAGONISTS are commonly used in the symptomatic treatment of anxiety but are not included here. (See all compounds classified as Anti-Anxiety Agents.)","Melting Point":"166-167 °C","MolecularFormula":"C\u003csub\u003e16\u003c/sub\u003eH\u003csub\u003e12\u003c/sub\u003eFN\u003csub\u003e3\u003c/sub\u003eO\u003csub\u003e3\u003c/sub\u003e","MolecularWeight":"313.28 g/mol","Pharmacodynamics":"Flunitrazepam is a powerful hypnotic drug that is a benzodiazepine derivative. It has powerful hypnotic, sedative, anxiolytic, and skeletal muscle relaxant properties. The drug is sometimes used as a date rape drug. In the United States, the drug has not been approved by the Food and Drug Administration for medical use, and is considered to be an illegal drug. It has however been approved in the United Kingdom and other countries.","Physical Description":"Solid","PubChemId":3380,"Record Description":["Flunitrazepam is a 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia. It has a role as a sedative, a GABAA receptor agonist and an anxiolytic drug. It is a 1,4-benzodiazepinone, a C-nitro compound and a member of monofluorobenzenes.","Flunitrazepam is a DEA Schedule IV controlled substance. Substances in the DEA Schedule IV have a low potential for abuse relative to substances in Schedule III. It is a Depressants substance.","Flunitrazepam is a benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.","FLUNITRAZEPAM is a small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in at least one region.","A benzodiazepine with pharmacologic actions similar to those of diazepam that can cause anterograde amnesia. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug. [PubChem]","A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.","Flunitrazepam is a 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia. It has a role as a sedative, a GABAA receptor agonist and an anxiolytic drug. It is a 1,4-benzodiazepinone, a C-nitro compound and a member of monofluorobenzenes."],"References":[{"name":"Wikipedia","url":"https://en.wikipedia.org/wiki/Flunitrazepam"},{"name":"Wikidata","url":"https://www.wikidata.org/wiki/Q62947"},{"name":"DrugBank","url":"https://go.drugbank.com/drugs/DB01544"},{"name":"PubChem","url":"https://pubchem.ncbi.nlm.nih.gov/compound/3380"},{"name":"ChemSpider","url":"https://www.chemspider.com/Chemical-Structure.3263.html"},{"name":"ChEMBL","url":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL13280"},{"name":"ChEBI","url":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:31622"},{"name":"Common Chemistry","url":"https://commonchemistry.cas.org/detail?cas_rn=1622-62-4"},{"name":"HMDB","url":"https://hmdb.ca/metabolites/HMDB0015510"},{"name":"KEGG","url":"https://www.kegg.jp/entry/D01230"},{"name":"UNII","url":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/620X0222FQ"},{"name":"EPA DSSTox","url":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID7023065"}],"SMILES":"CN1C(=O)CN=C(C2=C1C=CC(=C2)[N+](=O)[O-])C3=CC=CC=C3F","Salts":["hydrochloride"],"Solubility":"8.58e-03 g/L","Stability/Shelf Life":"Study has been undertaken to determine the stability of four benzodiazepines: clonazepam, midazolam, flunitrazepam \u0026 oxazepam in whole blood samples. Spiked blood was stored at four different temperatures (room temperature, 4 degrees C, -20 degrees C \u0026 -80 degrees C) \u0026 analysed at selected times during 1 yr. Determination was performed on the first, third \u0026 seventh day during the first wk, then once/wk for 3 wk, once every 2 wk for 4 wk, then once/month for 4 months \u0026 finally, once every 2 months. Extraction was performed using liquid-liquid extraction with 1-chlorobutane, while quantification was carried out using high performance liquid chromatography equipped with a photodiode-array ultraviolet detector. At room temperature, the concn of all benzodiazepines decreased over 1 yr to 100 \u0026 70% for low \u0026 high concns, respectively. At 4 °C, the decr was between 90 \u0026 100% for low concns \u0026 between 50 \u0026 80% for high concns. At -20 °C, the measured decr was between 10 \u0026 20% for high \u0026 low concns, respectively. At -80 °C, the measured loss was not significant at high concn except for midazolam. However, at low concn the determined decr was between 5 \u0026 12%. The data collected suggests that quantitative results concerning long-term stored samples should be interpreted with caution in forensic cases. Further investigations concerning the stability of drugs in whole blood or other biological samples, additional methods of identification \u0026 determination as well as the establishment of optimal storage conditions should be undertaken in forensic cases.","StructureBase64":"<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" height="95.8mm" version="1.2" viewBox="0 0 94.7 95.8" width="94.7mm">
      
    <desc>Generated by the Chemistry Development Kit (http://github.com/cdk)</desc>
      
    <g fill="#FF0D0D" stroke="#000000" stroke-linecap="round" stroke-linejoin="round" stroke-width=".7">
            
        <rect fill="#FFFFFF" height="96.0" stroke="none" width="95.0" x=".0" y=".0"/>
            
        <g class="mol" id="mol1">
                  
            <line class="bond" id="mol1bnd1" x1="64.133" x2="66.65" y1=".979" y2="12.023"/>
                  
            <line class="bond" id="mol1bnd2" x1="70.823" x2="82.352" y1="16.608" y2="19.293"/>
                  
            <g class="bond" id="mol1bnd3">
                        
                <line x1="81.036" x2="88.456" y1="18.986" y2="9.724"/>
                        
                <line x1="82.939" x2="90.359" y1="20.511" y2="11.248"/>
                      
                <line class="hi" stroke="#FF0D0D" x1="88.456" x2="84.74600000000001" y1="9.724" y2="14.355"/>
                <line class="hi" stroke="#FF0D0D" x1="90.359" x2="86.649" y1="11.248" y2="15.8795"/>
            </g>
                  
            <line class="bond" id="mol1bnd4" x1="82.352" x2="88.956" y1="19.293" y2="33.009"/>
                  
            <line class="bond" id="mol1bnd5" x1="88.956" x2="84.139" y1="33.009" y2="43.013"/>
                  
            <g class="bond" id="mol1bnd6">
                        
                <line x1="67.519" x2="79.048" y1="50.179" y2="47.494"/>
                        
                <line x1="68.121" x2="78.495" y1="47.535" y2="45.119"/>
                      
                <line class="hi" stroke="#3050F8" x1="79.048" x2="73.2835" y1="47.494" y2="48.8365"/>
                <line class="hi" stroke="#3050F8" x1="78.495" x2="73.30799999999999" y1="45.119" y2="46.327"/>
            </g>
                  
            <line class="bond" id="mol1bnd7" x1="67.519" x2="55.632" y1="50.179" y2="40.629"/>
                  
            <g class="bond" id="mol1bnd8">
                        
                <line x1="55.632" x2="55.632" y1="40.629" y2="25.389"/>
                        
                <line x1="53.193" x2="53.193" y1="39.22" y2="26.797"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd9" x1="64.487" x2="55.632" y1="18.274" y2="25.389"/>
                  
            <line class="bond" id="mol1bnd10" x1="55.632" x2="42.424" y1="25.389" y2="17.769"/>
                  
            <g class="bond" id="mol1bnd11">
                        
                <line x1="42.424" x2="29.216" y1="17.769" y2="25.389"/>
                        
                <line x1="42.424" x2="31.654" y1="20.584" y2="26.797"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd12" x1="29.216" x2="29.216" y1="25.389" y2="40.629"/>
                  
            <g class="bond" id="mol1bnd13">
                        
                <line x1="29.216" x2="42.424" y1="40.629" y2="48.249"/>
                        
                <line x1="31.654" x2="42.424" y1="39.22" y2="45.434"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd14" x1="55.632" x2="42.424" y1="40.629" y2="48.249"/>
                  
            <line class="bond" id="mol1bnd15" x1="29.216" x2="21.666" y1="40.629" y2="44.989"/>
                  
            <g class="bond" id="mol1bnd16">
                        
                <line x1="12.256" x2="5.486" y1="47.487" y2="43.579"/>
                        
                <line x1="13.475" x2="6.705" y1="45.375" y2="41.468"/>
                      
                <line class="hi" stroke="#3050F8" x1="12.256" x2="8.871" y1="47.487" y2="45.533"/>
                <line class="hi" stroke="#3050F8" x1="12.256" x2="8.871" y1="47.487" y2="45.533"/>
                <line class="hi" stroke="#FF0D0D" x1="5.486" x2="8.871" y1="43.579" y2="45.533"/>
                <line class="hi" stroke="#3050F8" x1="13.475" x2="10.09" y1="45.375" y2="43.4215"/>
                <line class="hi" stroke="#3050F8" x1="13.475" x2="10.09" y1="45.375" y2="43.4215"/>
                <line class="hi" stroke="#FF0D0D" x1="6.705" x2="10.09" y1="41.468" y2="43.4215"/>
            </g>
                  
            <line class="bond" id="mol1bnd17" x1="16.019" x2="16.02" y1="52.101" y2="59.539"/>
                  
            <line class="bond" id="mol1bnd18" x1="67.519" x2="64.133" y1="50.179" y2="65.038"/>
                  
            <g class="bond" id="mol1bnd19">
                        
                <line x1="64.133" x2="49.654" y1="65.038" y2="69.532"/>
                        
                <line x1="63.507" x2="51.717" y1="67.786" y2="71.445"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd20" x1="49.654" x2="46.244" y1="69.532" y2="84.386"/>
                  
            <g class="bond" id="mol1bnd21">
                        
                <line x1="46.244" x2="57.313" y1="84.386" y2="94.745"/>
                        
                <line x1="48.934" x2="57.948" y1="83.564" y2="92.0"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd22" x1="57.313" x2="71.891" y1="94.745" y2="90.274"/>
                  
            <g class="bond" id="mol1bnd23">
                        
                <line x1="71.891" x2="75.301" y1="90.274" y2="75.421"/>
                        
                <line x1="69.83" x2="72.61" y1="88.356" y2="76.248"/>
                      
            </g>
                  
            <line class="bond" id="mol1bnd24" x1="64.133" x2="75.301" y1="65.038" y2="75.421"/>
                  
            <line class="bond" id="mol1bnd25" x1="75.301" x2="87.165" y1="75.421" y2="71.776"/>
                  
            <path class="atom" d="M69.46 18.288h-.721l-2.619 -4.066h-.03q.012 .238 .03 .595q.024 .357 .024 .733v2.738h-.566v-4.899h.715l2.607 4.054h.03q-.006 -.108 -.018 -.328q-.012 -.22 -.024 -.476q-.006 -.262 -.006 -.482v-2.768h.578v4.899z" fill="#3050F8" id="mol1atm2" stroke="none"/>
                  
            <path class="atom" d="M94.14 7.396q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM90.277 7.396q-.0 .923 .387 1.458q.393 .53 1.22 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm4" stroke="none"/>
                  
            <path class="atom" d="M84.293 49.174h-.72l-2.62 -4.066h-.029q.012 .239 .029 .596q.024 .357 .024 .732v2.738h-.565v-4.899h.714l2.608 4.054h.029q-.006 -.107 -.018 -.327q-.011 -.221 -.023 -.477q-.006 -.262 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" id="mol1atm6" stroke="none"/>
                  
            <g class="atom" id="mol1atm14">
                        
                <path d="M17.959 50.7h-.72l-2.619 -4.065h-.03q.012 .238 .03 .595q.023 .357 .023 .732v2.738h-.565v-4.899h.714l2.608 4.054h.03q-.006 -.107 -.018 -.327q-.012 -.221 -.024 -.477q-.006 -.261 -.006 -.482v-2.768h.577v4.899z" fill="#3050F8" stroke="none"/>
                        
                <path d="M19.635 45.656h.818v.293h-.818v.847h-.296v-.847h-.818v-.293h.818v-.85h.296v.85z" fill="#3050F8" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M5.078 40.63q.0 .756 -.256 1.327q-.256 .566 -.756 .882q-.5 .315 -1.244 .315q-.756 .0 -1.262 -.315q-.506 -.316 -.756 -.887q-.244 -.572 -.244 -1.334q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM1.215 40.63q-.0 .923 .387 1.458q.393 .53 1.22 .53q.84 .0 1.221 -.53q.387 -.535 .387 -1.458q-.0 -.929 -.387 -1.453q-.381 -.524 -1.209 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" id="mol1atm15" stroke="none"/>
                  
            <g class="atom" id="mol1atm16">
                        
                <path d="M18.28 63.488q.0 .756 -.256 1.327q-.256 .566 -.756 .881q-.5 .316 -1.244 .316q-.756 -.0 -1.262 -.316q-.506 -.315 -.756 -.887q-.244 -.571 -.244 -1.333q-.0 -.75 .244 -1.31q.25 -.565 .756 -.881q.506 -.315 1.274 -.315q.732 -.0 1.232 .315q.5 .31 .756 .875q.256 .566 .256 1.328zM14.417 63.488q-.0 .923 .387 1.458q.393 .53 1.22 .53q.839 .0 1.22 -.53q.387 -.535 .387 -1.458q.0 -.929 -.387 -1.453q-.381 -.524 -1.208 -.524q-.833 .0 -1.226 .524q-.393 .524 -.393 1.453z" stroke="none"/>
                        
                <path d="M20.774 60.823v.293h-1.932v-.293h1.932z" stroke="none"/>
                      
            </g>
                  
            <path class="atom" d="M89.116 73.395h-.613v-4.9h2.733v.542h-2.12v1.738h1.995v.542h-1.995v2.078z" fill="#90E050" id="mol1atm23" stroke="none"/>
                
            <line class="hi" id="mol1bnd1" stroke="#3050F8" x1="66.65" x2="65.39150000000001" y1="12.023" y2="6.5009999999999994"/>
            <line class="hi" id="mol1bnd2" stroke="#3050F8" x1="70.823" x2="76.5875" y1="16.608" y2="17.950499999999998"/>
            <line class="hi" id="mol1bnd5" stroke="#3050F8" x1="84.139" x2="86.5475" y1="43.013" y2="38.010999999999996"/>
            <line class="hi" id="mol1bnd9" stroke="#3050F8" x1="64.487" x2="60.0595" y1="18.274" y2="21.8315"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="21.666" x2="25.441000000000003" y1="44.989" y2="42.809"/>
            <line class="hi" id="mol1bnd15" stroke="#3050F8" x1="21.666" x2="25.441000000000003" y1="44.989" y2="42.809"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="16.019" x2="16.0195" y1="52.101" y2="55.82"/>
            <line class="hi" id="mol1bnd17" stroke="#3050F8" x1="16.019" x2="16.0195" y1="52.101" y2="55.82"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="16.02" x2="16.0195" y1="59.539" y2="55.82"/>
            <line class="hi" id="mol1bnd17" stroke="#FF0D0D" x1="16.02" x2="16.0195" y1="59.539" y2="55.82"/>
            <line class="hi" id="mol1bnd25" stroke="#90E050" x1="87.165" x2="81.233" y1="71.776" y2="73.5985"/>
        </g>
          
    </g>
    
</svg>
","Therapeutic Uses":"Anti-Anxiety Agents; GABA Modulators","Title":"Flunitrazepam","UNII":"620X0222FQ","Wikidata":"Q62947","XLogP":2.1}